These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 2985703

  • 1. Cyclic AMP-dependent protein kinase in Molt 4b lymphoblasts: identification by photoaffinity labeling and activation in intact cells by vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI).
    O'Dorisio MS, Wood CL, Wenger GD, Vassalo LM.
    J Immunol; 1985 Jun; 134(6):4078-86. PubMed ID: 2985703
    [Abstract] [Full Text] [Related]

  • 2. Vasoactive intestinal peptide effects on GH3 pituitary tumor cells: high affinity binding, affinity labeling, and adenylate cyclase stimulation. Comparison with peptide histidine isoleucine and growth hormone-releasing factor.
    Wood CL, O'Dorisio MS, Vassalo LM, Malarkey WB, O'Dorisio TM.
    Regul Pept; 1985 Nov 07; 12(3):237-48. PubMed ID: 3001842
    [Abstract] [Full Text] [Related]

  • 3. VIP modulates intracellular calcium oscillations in human lymphoblasts.
    Anton PA, Shanahan F, Sun XP, Diehl D, Kodner A, Mayer EA.
    Immunopharmacol Immunotoxicol; 1993 Aug 07; 15(4):429-46. PubMed ID: 8227970
    [Abstract] [Full Text] [Related]

  • 4. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
    Zawilska JB, Niewiadomski P, Nowak JZ.
    Gen Comp Endocrinol; 2004 Jun 07; 137(2):187-95. PubMed ID: 15158130
    [Abstract] [Full Text] [Related]

  • 5. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA, O'Dorisio MS, Cox MO, Lara-Marquez M, Goetzl EJ.
    J Pharmacol Exp Ther; 2003 Aug 07; 306(2):638-45. PubMed ID: 12750439
    [Abstract] [Full Text] [Related]

  • 6. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice.
    Rangon CM, Goursaud S, Medja F, Lelièvre V, Mounien L, Husson I, Brabet P, Jégou S, Janet T, Gressens P.
    J Pharmacol Exp Ther; 2005 Aug 07; 314(2):745-52. PubMed ID: 15872042
    [Abstract] [Full Text] [Related]

  • 7. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
    Zawilska JB, Niewiadomski P, Nowak JZ.
    Pol J Pharmacol; 2004 Aug 07; 56(2):203-11. PubMed ID: 15156071
    [Abstract] [Full Text] [Related]

  • 8. Vasoactive intestinal peptide receptor/adenylate cyclase system: differences between agonist- and protein kinase C-mediated desensitization and further evidence for receptor internalization.
    Turner JT, Bollinger DW, Toews ML.
    J Pharmacol Exp Ther; 1988 Nov 07; 247(2):417-23. PubMed ID: 2846820
    [Abstract] [Full Text] [Related]

  • 9. Vasoactive intestinal peptide and neuropeptide modulation of the immune response.
    O'Dorisio MS, Wood CL, O'Dorisio TM.
    J Immunol; 1985 Aug 07; 135(2 Suppl):792s-796s. PubMed ID: 2861233
    [Abstract] [Full Text] [Related]

  • 10. Cyclic AMP formation in C6 glioma cells: effect of PACAP and VIP in early and late passages.
    Sokolowska P, Nowak JZ.
    Ann N Y Acad Sci; 2006 Jul 07; 1070():566-9. PubMed ID: 16888226
    [Abstract] [Full Text] [Related]

  • 11. Cyclic AMP formation in chicken brain: effect of vasoactive intestinal peptide, peptide histidine-isoleucine (PHI), and some PHI-related peptides.
    Dejda A, Matczak I, Wiktorowska-Owczarek A, Nowak JZ.
    Pol J Pharmacol; 2003 Jul 07; 55(5):747-51. PubMed ID: 14704471
    [Abstract] [Full Text] [Related]

  • 12. Demonstration of a functional receptor for vasoactive intestinal polypeptide on Molt 4b T lymphoblasts.
    Beed EA, O'Dorisio MS, O'Dorisio TM, Gaginella TS.
    Regul Pept; 1983 Apr 07; 6(1):1-12. PubMed ID: 6306732
    [Abstract] [Full Text] [Related]

  • 13. PACAP, VIP, and PHI: effects on AC-, PLC-, and PLD-driven signaling systems in the primary glial cell cultures.
    Dejda A, Jozwiak-Bebenista M, Nowak JZ.
    Ann N Y Acad Sci; 2006 Jul 07; 1070():220-5. PubMed ID: 16888170
    [Abstract] [Full Text] [Related]

  • 14. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes.
    Mittag TW, Tormay A, Podos SM.
    J Pharmacol Exp Ther; 1987 Apr 07; 241(1):230-5. PubMed ID: 3033201
    [Abstract] [Full Text] [Related]

  • 15. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
    Goursaud S, Pineau N, Becq-Giraudon L, Gressens P, Muller JM, Janet T.
    J Neuroimmunol; 2005 Jan 07; 158(1-2):94-105. PubMed ID: 15589042
    [Abstract] [Full Text] [Related]

  • 16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Immunol; 1999 Feb 01; 162(3):1707-16. PubMed ID: 9973433
    [Abstract] [Full Text] [Related]

  • 17. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S, Kopras E, McMichael M, Bell RH, Ulrich CD.
    Cancer Res; 1997 Apr 15; 57(8):1475-80. PubMed ID: 9108448
    [Abstract] [Full Text] [Related]

  • 18. Identification of vasoactive intestinal peptide receptor subtypes in the lacrimal gland and their signal-transducing components.
    Hodges RR, Zoukhri D, Sergheraert C, Zieske JD, Dartt DA.
    Invest Ophthalmol Vis Sci; 1997 Mar 15; 38(3):610-9. PubMed ID: 9071214
    [Abstract] [Full Text] [Related]

  • 19. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
    Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.
    J Immunol; 1999 Apr 15; 162(8):4685-96. PubMed ID: 10202009
    [Abstract] [Full Text] [Related]

  • 20. Effects of forskolin on adenylate cyclase activity and amylase secretion in the rat exocrine pancreas.
    Dehaye JP, Gillard M, Poloczek P, Stievenart M, Winand J, Christophe J.
    J Cyclic Nucleotide Protein Phosphor Res; 1985 Apr 15; 10(3):269-80. PubMed ID: 2410466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.